

Review Article

Animal Models of GWAS-Identified Type 2 Diabetes Genes

**Gabriela da Silva Xavier,¹ Elisa A. Bellomo,¹ James A. McGinty,²
Paul M. French,² and Guy A. Rutter¹**

¹ Section of Cell Biology, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London, London SW7 2AZ, UK

² Biophotonics Section, Department of Physics, Imperial College London, London SW7 2AZ, UK

Correspondence should be addressed to Guy A. Rutter; g.rutter@imperial.ac.uk

Received 4 February 2013; Accepted 18 March 2013

Academic Editor: Daisuke Koya

Copyright © 2013 Gabriela da Silva Xavier et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More than 65 *loci*, encoding up to 500 different genes, have been implicated by genome-wide association studies (GWAS) as conferring an increased risk of developing type 2 diabetes (T2D). Whilst mouse models have in the past been central to understanding the mechanisms through which more penetrant risk genes for T2D, for example, those responsible for neonatal or maturity-onset diabetes of the young, only a few of those identified by GWAS, notably *TCF7L2* and *ZnT8/SLC30A8*, have to date been examined in mouse models. We discuss here the animal models available for the latter genes and provide perspectives for future, higher throughput approaches towards efficiently mining the information provided by human genetics.

1. Introduction

The estimated global prevalence for diabetes in 2011 was 366 million, and the disease is expected to affect 552 million people by 2030 (Diabetes U.K. figures; [1] accessed 09/01/13). Type 2 diabetes (T2D) is a complex and multifactorial disease characterised by impaired insulin secretion and insulin resistance. Disease risk/progression is determined by a combination of genetic and environmental factors. It has been consistently demonstrated that lifestyle factors are associated with risk of T2D across populations [2–8], with increased adiposity being the greatest modifiable risk factor for the disease [9, 10]. Inactivity [3, 11], “bad” diet [2, 6, 8, 12–14], smoking, and other vices [8, 15, 16] and the nutritional environment during pre- and postnatal life [17] also contribute to the risk for developing diabetes.

It has been estimated that 30–70% of T2D risk may be due to genetics [18]. Whilst pedigree-based linkage analysis and the candidate gene approach led to the discovery of highly penetrant genetic defects which account for the development of diabetes [19–24], it is the advent of large scale genome-wide association studies (GWAS) which have led to the accelerated discovery of risk-variants associated with T2D [25–34]. Currently, over 60 common risk variants have been

identified [30–34], with a combined disease risk of 5–10% [34, 35], suggesting the existence of many more as yet undiscovered loci [34, 36, 37]. Most of the GWAS-identified associations for T2D have high linkage disequilibrium with a causal variant with a small effect size; the largest common variant-signal identified to date is that for *TCF7L2*, which has a per allele odds ratio of 1.35 [27–29].

Most of the common variant signals identified by GWAS are associated with defective pancreatic islet function, indicating that this is the primary driver for the development of T2D [34, 38]. However, most of the GWAS signals map to noncoding regions of the genome, making it difficult to establish functional links to specific transcripts. As a result, determination both of (a) the identity of the likely transcript(s) involved and (b) the mechanisms of actions on disease risk, require the use of genetically tractable organisms where the expression of candidate genes can be manipulated at will in a cell type-specific manner. Of the available models (which include lower organisms such as *C. elegans*, *D. melanogaster*, etc.), mice arguably represent the best compromise between ease of genetic manipulation and similarity to man, in terms of both genome structure and physiology. In this review, we discuss the use of mouse models to study the contribution of genetic variations, identified by GWAS, in the *TCF7L2* and

SLC30A8 genes to the development of T2D via their effects on pancreatic islet function.

2. TCF7L2

2.1. Background. The gene-encoding Transcription 7 Like-2 (*TCF7L2*, previously called *TCF4*) is the most important T2D susceptibility gene identified to date, with genetic variants strongly associated with diabetes in all major racial groups [27–29, 39–59]. Signals in this locus are the most consistently identified across various GWAS and are associated with the highest elevation of risk of developing adult-onset T2D. Each copy of the risk *T*-allele at rs7903146 has an increased odds ratio for T2D of 1.4–1.5 [60]. Inheritance of the risk allele is also a useful predictor for the likelihood of conversion from a state of prediabetes to T2D [61, 62]. Additionally, results from a small number of studies also indicate that *TCF7L2* variation may play an important role in cases of early onset T2D [63, 64].

TCF7L2 is a member of the TCF family of transcription factors involved in the control of cell growth and signalling downstream of wingless-type MMTV integration site family (Wnt) receptors [65]. Activation of the Wnt pathway leads to release of β -catenin from an inhibitory complex and its translocation to the nucleus, where it binds *TCF7L2* and other related TCF factors [66]. The function of this transcriptional complex is context dependent; that is it may act as either a transcriptional activator or repressor [66].

In recent years, the product of the *TCF7L2* gene has been associated with dysregulated pancreatic β cell function and T2D [25, 27, 28]. Enhanced Wnt signalling has been shown to lead to proliferation of islets [67] and the pancreatic epithelium [68]. Whilst loss of β -catenin signalling has been shown to lead to pancreatic hypoplasia [69], stabilisation of β -catenin has been shown to result in the formation of large pancreatic tumours [70].

Individuals carrying the risk alleles of rs7903146 in the *TCF7L2* gene display lowered insulin secretion [61, 71, 72], impaired insulin processing [71], and decreased sensitivity to the incretin glucagon-like peptide 1 (GLP-1) [72, 73] compared to controls. *TCF7L2* message levels were elevated in T2D patients [72, 74], whilst *TCF7L2* protein content was depressed [75]. The decrease in protein content was associated with downregulation of GLP-1 and gastric inhibitory peptide (GIP) receptor expression and impaired pancreatic β cell function [74, 76, 77]. Studies have shown that silencing of *Tcf7l2* gene expression in clonal mouse β cell lines [76] and primary islets [75] leads to increased apoptosis [75] and impaired β cell function [19, 20]. Gene expression analysis following *Tcf7l2* silencing revealed changes in the expression of a number of genes in mouse pancreatic islets [76], one of which was *Glp1r* [73, 78]. *TCF7L2* may mediate GLP-1-induced β cell proliferation through activation of the Wnt signalling pathway [79]. Since GLP-1 is implicated in β cell survival, the increased incidence of apoptosis in *TCF7L2*-silenced islets [74, 75] and in individuals carrying the variants of *TCF7L2* [73] is consistent with lowered GLP-1 signalling [73, 78]. Correspondingly, the diminished insulinotropic effect of GLP-1 in *Tcf7l2*-silenced islets may be due,

at least in part, to the lack of cognate receptors on the cell surface [74].

2.2. Mouse Models for TCF7L2

2.2.1. Whole Body Knockout Model. Prior to its association with T2D, *TCF7L2* was previously best known for its association with cancer development [80–82]. Homozygous *Tcf7l2* knockout (*Tcf7l2*^{-/-}) mice die shortly after birth, with a lack of stem cells in their intestinal crypts [83]. Newborn *Tcf7l2*^{-/-} mice have reduced body weight with significantly lower blood glucose 3 h postpartum than control littermates, which is not caused by excessive insulin release but by impaired carbohydrate and lipid metabolism in the newborn liver [84].

Heterozygote *Tcf7l2*^{+/-} mice display >20% decrease in body weight compared to wild-type littermates, with decreased glucose, insulin, fatty acid, triglyceride, and cholesterol in adult mice [84]. *Tcf7l2*^{+/-} mice displayed increased insulin sensitivity, improved glucose tolerance, and reduced hepatic glucose output [84, 85]. Improved glucose tolerance was also observed in heterozygote null mice generated using zinc finger nucleases [85] and insertion of a loxP site and FRT-flanked neomycin selection cassette within intron 4 and a loxP site within intron 5 [86], with data from the latter study also pointing to reduced lipogenesis and hepatic triglyceride levels and decreased peripheral fat deposition following exposure to a high fat diet in heterozygote mice compared to control littermates.

Pancreatic development is grossly normal in *Tcf7l2*^{-/-} mice [83, 84]. This observation and a report suggesting that *TCF7L2* was not expressed in the pancreas [87] led to the proposal that the principle defect underlying decreased insulin production in TC- or TT-bearing individuals may be inadequate production of GLP-1, from gut L-cells [88]. However, evidence for differences in GLP-1 level in individuals with the common *versus* the at-risk *TCF7L2* allele is currently absent [89], and patient studies have indicated that the primary defect lies in pancreatic β cells [71, 72, 75]. For this reason, mouse models which allow *Tcf7l2* gene expression to be selectively ablated in the islet were required.

2.2.2. Pancreas Knockout Model. We used the *Pdx1* promoter-driven Cre recombinase (*PDX1.Cre*) deleter strain [90] to effect deletion in all cells of pancreatic lineage in transgenic mice with a floxed *Tcf7l2* exon 1 to address the question whether selective deletion of *Tcf7l2* in pancreas impairs or improves glucose homeostasis and insulin secretion [77]. This approach allowed us to detect the potential effects of *Tcf7l2* deletion early in pancreatic development, as *TCF7L2* has previously been shown to regulate cell proliferation during development: the *Tcf7l2*^{-/-} mouse exhibited defects in the accumulation of stem cells in the intestinal crypt [83]. This approach also offered an advantage over the use of the commonly deployed rat insulin 2-promoter-driven Cre recombinase (*RIP2.Cre*) deleter strain since the latter also leads to deletion in the central nervous system [91–93]. Pancreas-specific *Tcf7l2*^{-/-} (*pTcf7l2*) mice showed age-dependent glucose intolerance by 20 weeks of age when

challenged with an intraperitoneal glucose bolus [77]. Glucose intolerance was detected from 12 weeks of age when glucose was administered by the oral route, indicating that the incretin response was impaired [77]. Tolerance to glucose introduced by both the oral and intraperitoneal route was exacerbated in pTcf7l2 mice that were exposed to a high fat diet, with a concomitant decrease in β cell mass [77]. The latter observation is consistent with observations by Shu and colleagues in high-fat-fed rats [94], where the authors found a correlation of *Tcf7l2* expression and β cell regeneration from pancreatic ductal cells and may reflect the inability of β cells to proliferate or regenerate from progenitor cells in the absence of functional *Tcf7l2*. The decreased expression of the *cyclin D1* gene [77] from islets of Langerhans extracted from 20-week-old pTcf7l2 mice may contribute towards the lack of cell proliferation.

pTcf7l2^{-/-} islets displayed impaired glucose and GLP-1-stimulated insulin secretion and decreased expression of the gene encoding for the GLP-1 receptor [77], consistent with *in vitro* human and mouse islet and cell line siRNA-mediated-silencing experiments [74–76]. Whilst the PDX1.Cre strain is likely to result in deletion in other (non- β) cell types [95], we observed no difference in plasma glucagon and GLP-1 levels and in insulin sensitivity in pTcf7l2 mice [77]. Our preliminary data obtained using a more β cell selective deleter strain (Ins1.Cre; J. Ferrer, B. Thorens, unpublished) also indicate deficiencies in insulin secretion and glucose tolerance, suggesting that *TCF7L2* plays a critical and cell autonomous role in the β cell compartment.

2.2.3. β Cell Knockout Model. Recently, Boj and colleagues generated a β cell *Tcf7l2* knockout (β TCF4KO) mouse using the tamoxifen inducible RIP2.Cre-ER^{T2} deleter strain [96] bred against a conditional mouse-bearing *Tcf7l2* alleles with a floxed exon 10 [84]. Although the use of the RIP2.Cre-ER^{T2} may affect metabolic phenotype through the expression of Cre recombinase in islet cells as well as in hypothalamic neurons [95], it is unclear whether *Tcf7l2* expression was affected in the hypothalamus of β TCF4KO mice.

β TCF4KO mice on normal or high fat diet displayed normal glucose tolerance when glucose was introduced by the intraperitoneal route [84]. There was no difference in plasma insulin and insulin release from isolated islets of β TCF4KO mice, *versus* control littermates, in response to glucose challenge [84]. Importantly, however, mice were not examined beyond 12 weeks of age, and oral glucose tolerances were not reported in this later study.

2.2.4. Transgenic Models. In the three previous mouse models described in this section, *Tcf7l2* gene expression was ablated either constitutively [83] or specifically in islet cells [77, 84]. Savic and colleagues took a different approach whereby they engineered mice that expressed LacZ under the control of human bacterial artificial chromosomes (BACs) containing the genomic interval encompassing the diabetes associated SNPs (which are intronic) for *TCF7L2* [85]. Using this technique, they demonstrated the presence of enhancer function in the SNPs-containing region which drives expression in,

for example, intestine and pancreas, but not in adult islets [85]. Transgenic mice with *Tcf7l2* overexpression driven by the human BAC sequence exhibited glucose intolerance when placed on a high fat diet [85]. These data are consistent with that presented by Gaulton and colleagues [103] indicating that the chromatin of the *TCF7L2* intronic variant is in an islet-specific “open” conformation, and reporter assays demonstrated increased enhancer activity of the at-risk *T*-allele compared with the *C*-allele in β cell lines.

The discrepancy in data between the various mouse models could be partly due to the involvement of *TCF7L2* in glucose homeostasis in more than one tissue, and at different times during development. The *Tcf7l2* gene was manipulated in different ways in the various experimental models and this may alter the tissue-specific splicing of the gene [104–107]. The expression of different variants may lead to different outcomes in different tissue types [104–107]. Analysis of glucose homeostasis at different time points during the life time of the animals and exposure to differing amounts of time to diets with different fat composition could all contribute to the differences in observations.

3. ZnT8 (SLC30A8)

3.1. Background. ZnT8 (encoding by the *SLC30A8* gene) is a member of the zinc transporter family (ZnTs) important for extruding zinc from the cytosol into either the extracellular space or intracellular organelles [108]. In particular, the expression of ZnT8 is largely (but not exclusively) restricted to α and β cells of the islets of Langerhans, where the mature protein resides chiefly on the limiting membrane of dense core secretory granule [97, 109, 110]. Its function thus, appears to be chiefly to transport Zn²⁺ from the cytosol into the granules where, in beta cells, this is required for insulin crystallisation [111]. By contrast, the role of Zn²⁺ in glucagon storage in the pancreatic alpha cell granule is not fully understood.

From the discovery that a single nucleotide polymorphism in the *SLC30A8* gene leads to an increased risk of developing T2D [27, 29], much work has been done to elucidate the function of the encoded protein and the role that ZnT8 plays in the pathogenesis of the disease. In contrast with the majority of GWAS-identified polymorphisms, rs13266634 in the *SLC30A8* gene encodes the replacement of Trp for Arg at position 325 (R325W) at the C-terminus of the protein and is associated with a ~20% increased risk of developing T2D per allele [28]. Given the highly restricted expression pattern of the transporter, hopes have been raised that ZnT8 may provide an exciting new drug target to enhance insulin release in diabetic patients.

3.2. Mouse Models Exploring ZnT8/SLC30A8 Function. A number of mouse models have been generated in order to elucidate the function of this molecule and its role in the pathogenesis of diabetes. These include whole body [97, 99–101] and cell type-specific (α or β cell) [102] ZnT8 knockout animals. Systemic ZnT8 knockout models have up to now been investigated by three different groups [97, 99–101]. These studies have revealed gross abnormalities (albeit age

TABLE 1: Summary of the major phenotype of the different colonies of ZnT8 KO mice. ZnT8- α KO and ZnT8- β KO for α and β -cell-specific knockout mice, respectively; GSIS for glucose-stimulated insulin secretion.

Phenotype/model	ZnT8KO-London [97]	ZnT8KO-Toronto [98]	ZnT8KO-Leuven [99]	ZnT8KO-Vanderbilt [100] (129SvEv ^{Brd} × C57BL/6J)	ZnT8KO-Vanderbilt [101] (C57BL/6J)	ZnT8- α KO	ZnT8- β KO [102]
Glucose tolerance							
≤6 weeks	♂ intolerant	♂ intolerant ♀ intolerant	Normal		♂ intolerant	Normal	Intolerant
12 weeks	♂ intolerant ♀ normal	♂ normal ♀ intolerant	Normal				
≥18 weeks			Normal	Normal	Normal		
Insulin sensitivity	Normal	Normal	Normal	Normal	Normal		
Plasma glucose		♂: Elevated (fasting) at 6 wks, normal afterwards. ♀: Normal	Normal	Normal	Normal (fasting)		
Plasma insulin		Decreased	Normal	Decreased	Normal (fasting)	Normal. (Plasma glucagon normal.)	Normal
Islet insulin content			Normal (glucagon content was normal.)	Normal	Normal		
Insulin secretion							
<i>In vivo</i>		Reduced					
<i>In vitro</i>	Basal secretion enhanced GSIS normal	GSIS enhanced	GSIS normal	GSIS reduced	GSIS normal		Reduced first phase
Glucagon secretion		Unaffected					
Insulin processing	Normal		Normal				
Granule morphology	Abnormal	Abnormal	Abnormal		Normal	Normal	Abnormal

and gender dependent) in insulin crystallisation and storage [97, 99] (Figure 1(a)), confirming the importance of ZnT8 in granular zinc accumulation. Nonetheless, significant differences were apparent both in terms of the regulation of insulin secretion and whole body glucose homeostasis. These differences are likely the result of subtle differences in genetic background, gender, and the age of the animals. Local environmental factors including diet and gut microbiome may also play a role [112]. Thus, glucose tolerance was found to be impaired at an early age (4–6 weeks of age) in three of these studies but not at an older age (>18 weeks) [97, 99, 100], suggesting that the penetrance of the phenotype decreases with age. While insulin sensitivity was unaltered in all of the studies, defects in insulin secretion were reported in two of the studies [97, 100]. None of these changes was associated with altered beta cell mass (Figures 1(b) and 1(c)) These data support the view that decreased ZnT8 activity is likely to influence glucose homeostasis in man and may underlie

the defects which increase the risk of developing T2D. Differences in the phenotype are summarised in Table 1.

Of note, the two recent studies of Pound et al. stress the importance of the genetic background. In the first [100], the genetically modified animals were maintained on a mixed background, while in the second [101], the mice were backcrossed onto a pure C57BL/6 background. Strikingly, whereas glucose-stimulated insulin secretion was unaltered in islets from ZnT8 knockout mice on a pure C57BL/6 background, islets from mice on the mixed background showed clear abnormalities in this parameter. Again, plasma insulin was decreased in the mixed background animals, while it was found normal in mice on a pure background. Since these mice were generated and kept in the same animal facility, it seems reasonable to exclude environmental differences as playing a role. Instead, these data support the view that background is a critical determinant of the penetrance of null ZnT8 alleles. Whether this impacts the preservation of functional β cell




FIGURE 1: Electron Micrographs and Optical Projection Tomography (OPT) in ZnT8^{+/+} and ZnT8^{-/-} mice. (a) Transmission electron microscopy images of isolated islets from ZnT8^{+/+} and ZnT8^{-/-} male mice at high magnification (scale bar 1 mm) reveals the appearance of rod-shaped core granules in ZnT8^{-/-} cells, indicated by red arrows ($n = 3$ mice). Sections were cut and images were acquired by Dr. Raffaella Carzaniga and Ms. Katrin Kronenberger. (b) Representative three-dimensional OPT projections of whole fixed and permeabilised pancreas from ZnT8^{-/-} and ZnT8^{+/+} mice. In red are the insulin positive structures (β cells). The overall shape of the whole pancreas was visualized as autofluorescence and is apparent as white/grey shading. Scale bar = 1 cm. (c) Relative (right panel) and absolute (left panel) β -cell volume ($n = 2$ pancreata per genotype).

mass in the face of differing insulin sensitivities between the strains, altered intracellular Zn^{2+} handling, or defective auto/paracrine Zn^{2+} signalling between islets cells remains to be elucidated.

As mentioned above, ZnT8 is present in both α and β cells such that the systemic knockout model reflects the impact of deletion from both cell types (and perhaps others where ZnT8 is expressed at low but detectable levels). The generation of cell-specific knockout models has therefore helped in understanding the contribution of each cell type to the overall phenotype observed. Wijesekara et al. described both the animal models in a recent paper [102]. Deletion of ZnT8 selectively from β cells (β ZnT8 null mice; using the RIP2 promoter) led to similar effects on glucose homeostasis as those observed in the systemic knockout developed by the same group and by ourselves [97], confirming that the transporter is required for proper insulin processing, crystallization, and packaging. However, β ZnT8 null mice displayed additional abnormalities in the expression of key genes required for normal glucose sensing in β cells. Whilst the underlying reasons for this greater penetrance are unclear, it is possible that changes in intracellular free Zn^{2+} levels are more marked in the β cell selective model since the α cell complement remains as an efficient sink for Zn^{2+} release, thus, more efficiently depleting β cell Zn^{2+} . Nonetheless, the broad similarities between ZnT8 whole body knockout and the β -cell-specific mouse model suggest that the phenotype of the former is primarily a consequence of ZnT8 deletion in β and not α cells; α cell-selective ZnT8 null mouse displayed unaltered glucose tolerance. However, glucagon secretion was not measured in these animals under conditions where the latter is likely to be physiologically important that is hypoglycaemia. It therefore remains possible that ZnT8 plays a significant role in the α cell, a possibility which awaits more detailed examination of α cell-selective null mice in the future.

Because T2D is a polygenic disease that is also influenced by environmental factors, it is important to mention new studies where ZnT8 knockout animals were maintained on a high fat content diet (HFD) [98, 99]. In both of these studies, ZnT8 null mice displayed an increase in body weight as well as fasting blood glucose and insulin levels compared to wild type controls. In particular, in one of these studies, 50% of the ZnT8 knockout animals became hyperglycemic after exposure to HFD, while none of the controls did so [99]. Each of these studies was performed using animals on a mixed (sv129/C57BL6) background. On the other hand, a further recent study using animals backcrossed onto a C57BL6 background [101] revealed that ZnT8 null animals were protected against the effects of high fat, again stressing the likely importance of modifier genes in determining the final penetrance of the effect. Although it is difficult to provide a straightforward rationalisation for these differences, it is noteworthy that sv129 mice are more insulin sensitive than C57BL6 animals [113], with the latter producing more insulin in hyperglycemic clamps. It is possible, therefore, that C57BL6 mice are better equipped to tolerate perturbations in insulin storage and secretion following *ZnT8* deletion.

These data reinforce the idea that mice, at least, are able to adapt metabolically to the loss of ZnT8 alleles under many circumstances. However, under metabolic stress, such as in the case of a diet rich in fat, the impact of defective insulin storage and or secretion are more apparent at least for mice on a mixed genetic background.

Whilst complete inactivation of ZnT8 in the mouse has been useful as a means of understanding the function of this protein, it is clear that more work needs to be done in order to elucidate the significance of the diabetes-associated polymorphism *in vivo*. At present, knock-in models for either the protective (W325) or risk (R325) forms of ZnT8 are missing and may be revealing, provided that the impact on transporter activity is sufficiently large [97]. Of note, such models would more closely mimic the situation in humans and help us to better understand the metabolic, signaling, and other pathways that are altered in tissues which express the transporter.

4. Perspectives

4.1. Better Mouse Models. A key point to bear in mind in assessing the usefulness of mouse models is the relative plasticity displayed by rodents faced with gene deletions. Thus, differences between the penetrance of mutations in human genes linked to monogenic forms of diabetes, including maturity onset diabetes of the young (MODY), between humans and mice, are usually observed [114] with the mouse equivalents showing far less marked disturbances in glycemia or changes which are seen only after deletion of both alleles. This clearly reflects the limitations of the use of mice (weight ~25 g, life expectancy ~3 years) for comparisons with human subjects. Nonetheless, and although the phenotypes of the above murine models are thus often more subtle than the human counterparts, they remain useful models for the study of diabetes, allowing single-targeted gene deletions which are impossible in man. For example, human populations with different genetic backgrounds have different susceptibility to the R235W ZnT8 polymorphism. We should not, therefore, find surprising the results that different genetic backgrounds and different diet reveal different phenotypes in ZnT8 knockout models.

The study of knockout mouse models is most useful if the likely target gene is clearly defined, as is the case when a SNP lies in an exon and encodes a nonsense or missense mutation (as for *SLC30A8*). One of the difficulties in studying the contribution of the SNPs identified for increased risk of T2D is that many of the SNPs identified to date mainly reside in intronic regions. This may be due to the technical limitations of identifying the disease-causing gene using current methods for GWAS, or that the disease-inducing variation may indeed reside in the intronic region of the gene, which may have regulatory function, as may be the case for *TCF7L2* [85]. Frequently, the sequences within the SNP regions are poorly conserved between mouse and man, for example, the sequences spanning SNP rs7903146 for *TCF7L2* lies within a repetitive element that is absent in mice. One possibility is to conduct physiological studies in “humanized” mice [85], but it is difficult to fully replicate the human

genetic environment in mouse models. Additionally, it is technically difficult to introduce targeted changes at high efficiency at precise locations. The emergence of genome modification technologies such as transcription activator-like effector nucleases (TALENs) [115–117] can substantially speed up the making of a tailored mutant animal model for whole system approaches to study the contribution of risk variants identified by GWAS to disease progression and may be useful in those instances where the region containing the variation is sufficiently similar to that found in humans. Importantly, such gene-editing approaches may also facilitate the use of alternative species (such as the rat or even the pig) whose physiology more closely resembles that of man.

An additional complication is that disease-causing SNPs do not exist in isolation. The genetic landscape of each individual may play a part in an individual's risk of developing a certain disease. For example, the risk of T2D is additive: the larger the number of risk SNPs present in an individual's genome, the higher the risk for the development of T2D [37, 118–121]. Thus, future animal models may require careful mapping of the genetic variations present in the model animal and the introduction of more than one genetic variation to model the diabetic phenotype conferred by these combined genetic variations.

4.2. Gene-Environment Interactions. An individual's risk of developing T2D is the product of interaction between the individual's genetic constitution and the environment inhabited by the individual. Whilst the contribution of genetic factors to disease risk is relatively easy to quantify, the impact of environmental exposure is less easily measured in a clinical setting. Nevertheless, efforts have been made to study the interactions between some of the known susceptibility *loci* for T2D and the environment, and these findings may be useful for the development of prediction models and tailoring clinical treatment for T2D [122, 123]. For example, for carriers of the risk allele for *TCF7L2*, diets of low glycaemic load [124, 125] and a more intensive lifestyle modification regime (*versus* that recommended for nonrisk carriers) [61, 62, 126, 127] have been shown to reduce the risk of T2D. Meaningful studies for gene-environment interactions will require samples of sufficient size to increase statistical power [128] and accurate methods for measuring environmental exposure, for example, the use of metabolomics to identify and assess metabolic characteristics, changes, and phenotypes in response to the environment, diet, lifestyle, and pathophysiological states. This information will allow the generation of better risk prediction models and personalisation/stratification of treatment, the holy grail of GWAS.

4.3. Cancer versus Diabetes (Opposing Mechanisms Hypothesis). One other observation from GWAS that should be mentioned, as it may have implications on treatment, is the link between cancer and T2D. There is epidemiological evidence that links T2D and cancer [129]. A large number of T2D genes found via GWAS are involved in cell cycle regulation [34], for example, the T2D association SNP mapping to chromosome 9p21 in the vicinity of the tumour suppressor genes *CDKN2A* and *CDKN2B* [130–132] and the *CDKN2B*

regulator *ANRIL* [133–135]. Recent genetic data suggest that common genetic variants influence cancer and diabetes in opposite directions [136, 137].

4.4. Which Genes Do We Study? A fundamental challenge facing those wishing to determine which of the genes in a particular locus is responsible for affecting disease risk, and dissect how this/these act, is the very scale of the problem (currently more than 500 genes in total to interrogate, with others emerging) [35] (and McCarthy M, personal communication). Clearly, new strategies will be required both to prioritise genes and thus develop models for those most likely to be involved: assessment of the impact of a particular variant (odds ratio) as well as expression profile (notably expression in β cells for those genes affecting insulin secretion), and finally, the likely biological impact of variations in a particular gene based on published knowledge are all essential to this process. Further, "experimental filtration" through higher throughput approaches (e.g., siRNA in β cell lines, including novel human lines [138]) are likely to be needed. Finally, more high throughput means to inactivate or overexpress genes in specific tissues in living mice without the need to engineer the latter via conventional recombination-based engineering of embryonic stem cells (e.g., through virus-mediated delivery) [139] and are likely to be increasingly important. A further challenge is that of understanding how the identified genes affect disease risk work via different tissues; systems and computational biology are likely to be highly important here.

Acknowledgments

This work is supported by Wellcome Trust Senior Investigator (WT098424AIA), Royal Society Wolfson Research Merit, MRC Programme (MR/J0003042/1), and Diabetes UK Studentship grants to Guy A. Rutter. Gabriela da Silva Xavier and Guy A. Rutter thank the European Foundation for the Study of Diabetes (EFSO) for Project grants. The work leading to this publication has also received support from the Innovative Medicines Initiative Joint Undertaking under Grant Agreement no. 155005 (IMIDIA), resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007–2013) and EFPIA companies' in kind contribution.

References

- [1] Diabetes UK, "Diabetes in the UK 2012: key statistics on diabetes," 2013.
- [2] F. B. Hu, "Globalization of diabetes: the role of diet, lifestyle, and genes," *Diabetes Care*, vol. 34, pp. 1249–1257, 2011.
- [3] F. B. Hu, T. Y. Li, G. A. Colditz, W. C. Willett, and J. E. Manson, "Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women," *Journal of the American Medical Association*, vol. 289, no. 14, pp. 1785–1791, 2003.
- [4] W. C. Knowler, E. Barrett-Connor, S. E. Fowler et al., "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin," *New England Journal of Medicine*, vol. 346, no. 6, pp. 393–403, 2002.

- [5] A. Ramachandran, C. Snehalatha, S. Mary, B. Mukesh, A. D. Bhaskar, and V. Vijay, "The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)," *Diabetologia*, vol. 49, no. 2, pp. 289–297, 2006.
- [6] J. Salas-Salvadó, M. Bulló, N. Babio et al., "Reduction in the incidence of type 2 diabetes with the mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial," *Diabetes Care*, vol. 34, no. 1, pp. 14–19, 2011.
- [7] J. Tuomilehto, J. Lindström, J. G. Eriksson et al., "Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance," *New England Journal of Medicine*, vol. 344, no. 18, pp. 1343–1350, 2001.
- [8] R. M. Van Dam, "The epidemiology of lifestyle and risk for type 2 diabetes," *European Journal of Epidemiology*, vol. 18, no. 12, pp. 1115–1125, 2003.
- [9] D. Yach, D. Stuckler, and K. D. Brownell, "Epidemiologic and economic consequences of the global epidemics of obesity and diabetes," *Nature Medicine*, vol. 12, pp. 62–66, 2006.
- [10] P. W. F. Wilson, J. B. Meigs, L. Sullivan, C. S. Fox, D. M. Nathan, and R. B. D'Agostino Sr., "Prediction of incident diabetes mellitus in middle-aged adults: the framingham offspring study," *Archives of Internal Medicine*, vol. 167, no. 10, pp. 1068–1074, 2007.
- [11] J. S. Rana, T. Y. Li, J. E. Manson, and F. B. Hu, "Adiposity compared with physical inactivity and risk of type 2 diabetes in women," *Diabetes Care*, vol. 30, no. 1, pp. 53–58, 2007.
- [12] V. S. Malik, B. M. Popkin, G. A. Bray, J. P. Després, W. C. Willett, and F. B. Hu, "Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis," *Diabetes Care*, vol. 33, no. 11, pp. 2477–2483, 2010.
- [13] U. Risérus, W. C. Willett, and F. B. Hu, "Dietary fats and prevention of type 2 diabetes," *Progress in Lipid Research*, vol. 48, no. 1, pp. 44–51, 2009.
- [14] A. W. Barclay, P. Petocz, J. McMillan-Price et al., "Glycemic index, glycemic load, and chronic disease risk—a metaanalysis of observational studies," *American Journal of Clinical Nutrition*, vol. 87, no. 3, pp. 627–637, 2008.
- [15] N. A. Christakis and J. H. Fowler, "The spread of obesity in a large social network over 32 years," *New England Journal of Medicine*, vol. 357, no. 4, pp. 370–379, 2007.
- [16] C. Willi, P. Bodenmann, W. A. Ghali, P. D. Faris, and J. Cornuz, "Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis," *Journal of the American Medical Association*, vol. 298, no. 22, pp. 2654–2664, 2007.
- [17] G. C. Burdge and K. A. Lillycrop, "Nutrition, epigenetics, and developmental plasticity: implications for understanding human disease," *Annual Review of Nutrition*, vol. 30, pp. 315–339, 2010.
- [18] P. Poulsen, K. Ohm Kyvik, A. Vaag, and H. Beck-Nielsen, "Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance—a population-based twin study," *Diabetologia*, vol. 42, no. 2, pp. 139–145, 1999.
- [19] K. Owen and A. T. Hattersley, "Maturity-onset diabetes of the young: from clinical description to molecular genetic characterization," *Best Practice and Research*, vol. 15, no. 3, pp. 309–323, 2001.
- [20] I. S. Farooqi and S. O'Rahilly, "Genetics of obesity in humans," *Endocrine Reviews*, vol. 27, no. 7, pp. 710–718, 2006.
- [21] N. Risch and K. Merikangas, "The future of genetic studies of complex human diseases," *Science*, vol. 273, no. 5281, pp. 1516–1517, 1996.
- [22] D. Altshuler, J. N. Hirschhorn, M. Klannemark et al., "The common PPAR γ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes," *Nature Genetics*, vol. 26, no. 1, pp. 76–80, 2000.
- [23] J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, "An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ)," *Journal of Biological Chemistry*, vol. 270, no. 22, pp. 12953–12956, 1995.
- [24] A. L. Gloyn, M. N. Weedon, K. R. Owen et al., "Large-scale association studies of variants in genes encoding the pancreatic β -cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes," *Diabetes*, vol. 52, no. 2, pp. 568–572, 2003.
- [25] S. F. A. Grant, G. Thorleifsson, I. Reynisdottir et al., "Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes," *Nature Genetics*, vol. 38, no. 3, pp. 320–323, 2006.
- [26] R. Saxena, B. F. Voight, V. Lyssenko et al., "Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels," *Science*, vol. 316, no. 5829, pp. 1331–1336, 2007.
- [27] L. J. Scott, K. L. Mohlke, L. L. Bonnycastle et al., "A genome-wide association study of type 2 diabetes in finns detects multiple susceptibility variants," *Science*, vol. 316, no. 5829, pp. 1341–1345, 2007.
- [28] R. Sladek, G. Rocheleau, J. Rung et al., "A genome-wide association study identifies novel risk loci for type 2 diabetes," *Nature*, vol. 445, no. 7130, pp. 881–885, 2007.
- [29] E. Zeggini, M. N. Weedon, C. M. Lindgren et al., "Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes," *Science*, vol. 316, pp. 1336–1341, 2007.
- [30] Y. S. Cho, C. H. Chen, C. Hu et al., "Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians," *Nature Genetics*, vol. 44, pp. 67–72, 2012.
- [31] J. Dupuis, C. Langenberg, I. Prokopenko et al., "New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk," *Nature Genetics*, vol. 42, pp. 105–116, 2010.
- [32] J. S. Kooner, D. Saleheen, X. Sim et al., "Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci," *Nature Genetics*, vol. 43, pp. 984–989, 2011.
- [33] N. D. Palmer, C. W. McDonough, P. J. Hicks et al., "A genome-wide association search for type 2 diabetes genes in African Americans," *PLoS ONE*, vol. 7, Article ID e29202, 2012.
- [34] B. F. Voight, L. J. Scott, V. Steinthorsdottir et al., "Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis," *Nature Genetics*, vol. 42, pp. 579–589, 2010.
- [35] A. P. Morris, B. F. Voight, T. M. Teslovich et al., "Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes," *Nature Genetics*, vol. 44, pp. 981–990, 2012.
- [36] M. C. Cornelis, L. Qi, C. Zhang et al., "Joint effects of common genetic variants on the risk for type 2 diabetes in U.S. men and women of European ancestry," *Annals of Internal Medicine*, vol. 150, no. 8, pp. 541–550, 2009.
- [37] J. M. De Miguel-Yanes, P. Shrader, M. J. Pencina et al., "Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms," *Diabetes Care*, vol. 34, no. 1, pp. 121–125, 2011.

- [38] J. C. Florez, "Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes?" *Diabetologia*, vol. 51, no. 7, pp. 1100–1110, 2008.
- [39] S. Cauchi, D. Meyre, C. Dina et al., "Transcription factor TCF7L2 genetic study in the French population: expression in human β -cells and adipose tissue and strong association with type 2 diabetes," *Diabetes*, vol. 55, no. 10, pp. 2903–2908, 2006.
- [40] S. Maeda, N. Osawa, T. Hayashi, S. Tsukada, M. Kobayashi, and R. Kikkawa, "Genetic variations associated with diabetic nephropathy and type II diabetes in a Japanese population," *Kidney International*, vol. 72, no. 106, supplement, pp. S43–S48, 2007.
- [41] J. B. Meigs, M. K. Rutter, L. M. Sullivan, C. S. Fox, R. B. D'Agostino, and P. W. F. Wilson, "Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome," *Diabetes Care*, vol. 30, no. 5, pp. 1219–1225, 2007.
- [42] C. Herder, W. Rathmann, K. Strassburger et al., "Variants of the PPAR γ , IGF2BP2, CDKAL1, HHEX, and TCF7L2 genes confer risk of type 2 diabetes independently of BMI in the German KORA studies," *Hormone and Metabolic Research*, vol. 40, no. 10, pp. 722–726, 2008.
- [43] D. K. Sanghera, L. Ortega, S. Han et al., "Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPAR γ 2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk," *BMC Medical Genetics*, vol. 9, article 59, 2008.
- [44] Y. M. Cho, T. H. Kim, S. Lim et al., "Type 2 diabetes-associated genetic variants discovered in the recent genome-wide association studies are related to gestational diabetes mellitus in the Korean population," *Diabetologia*, vol. 52, no. 2, pp. 253–261, 2009.
- [45] Y. Tabara, H. Osawa, R. Kawamoto et al., "Replication study of candidate genes associated with type 2 diabetes based on genome-wide screening," *Diabetes*, vol. 58, no. 2, pp. 493–498, 2009.
- [46] G. F. Marquezine, A. C. Pereira, A. G. P. Sousa, J. G. Mill, W. A. Hueb, and J. E. Krieger, "TCF7L2 variant genotypes and type 2 diabetes risk in Brazil: significant association, but not a significant tool for risk stratification in the general population," *BMC Medical Genetics*, vol. 9, article 106, 2008.
- [47] I. Ezzidi, N. Mtiraoui, S. Cauchi et al., "Contribution of type 2 diabetes associated loci in the Arabic population from Tunisia: a case-control study," *BMC Medical Genetics*, vol. 10, article 33, 2009.
- [48] F. Takeuchi, M. Serizawa, K. Yamamoto et al., "Confirmation of multiple risk loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese population," *Diabetes*, vol. 58, no. 7, pp. 1690–1699, 2009.
- [49] S. Erekat, A. Nasereddin, S. Cauchi, K. Azmi, Z. Abdeen, and R. Amin, "Association of a common variant in TCF7L2 gene with type 2 diabetes mellitus in the Palestinian population," *Acta Diabetologica*, vol. 47, no. 1, supplement, pp. S195–S198, 2010.
- [50] J. Wen, T. Rönn, A. Olsson et al., "Investigation of type 2 diabetes risk alleles support CDKN2A/B, CDKAL1, and TCF7L2 as susceptibility genes in a Han Chinese cohort," *PLoS ONE*, vol. 5, no. 2, Article ID e9153, 2010.
- [51] G. Chauhan, C. J. Spurgeon, R. Tabassum et al., "Impact of common variants of PPAR γ , KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians," *Diabetes*, vol. 59, no. 8, pp. 2068–2074, 2010.
- [52] R. Karns, G. Zhang, N. Jeran et al., "Replication of genetic variants from genome-wide association studies with metabolic traits in an island population of the Adriatic coast of Croatia," *European Journal of Human Genetics*, vol. 19, no. 3, pp. 341–346, 2011.
- [53] E. Ramos, G. Chen, D. Shriner et al., "Replication of genome-wide association studies (GWAS) loci for fasting plasma glucose in African-Americans," *Diabetologia*, vol. 54, no. 4, pp. 783–788, 2011.
- [54] S. D. Rees, M. Z. Hydrie, A. S. Shera et al., "Replication of 13 genome-wide association (GWA)-validated risk variants for type 2 diabetes in Pakistani populations," *Diabetologia*, vol. 54, pp. 1368–1374, 2011.
- [55] R. Saxena, C. C. Elbers, Y. Guo et al., "Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci," *American Journal of Human Genetics*, vol. 90, pp. 410–425, 2012.
- [56] S. Cauchi, I. Ezzidi, A. Y. El et al., "European genetic variants associated with type 2 diabetes in North African Arabs," *Diabetes & Metabolism*, vol. 38, pp. 316–323, 2012.
- [57] N. Mtiraoui, A. Turki, R. Nemr et al., "Contribution of common variants of ENPP1, IGF2BP2, KCNJ11, MLXIPL, PPAR γ , SLC30A8 and TCF7L2 to the risk of type 2 diabetes in Lebanese and Tunisian Arabs," *Diabetes & Metabolism*, vol. 38, pp. 444–449, 2012.
- [58] A. Turki, G. S. Al-Zaben, N. Mtiraoui, H. Marmmuoch, T. Mahjoub, and W. Y. Almawi, "Transcription factor-7-like 2 gene variants are strongly associated with type 2 diabetes in Tunisian Arab subjects," *Gene*, vol. 513, pp. 244–248, 2013.
- [59] J. Long, T. Edwards, L. B. Signorello et al., "Evaluation of genome-wide association study-identified type 2 diabetes loci in African Americans," *American Journal of Epidemiology*, vol. 176, pp. 995–1001, 2012.
- [60] A. Helgason, S. Pálsson, G. Thorleifsson et al., "Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution," *Nature Genetics*, vol. 39, no. 2, pp. 218–225, 2007.
- [61] J. C. Florez, K. A. Jablonski, N. Bayley et al., "TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program," *New England Journal of Medicine*, vol. 355, no. 3, pp. 241–250, 2006.
- [62] J. Wang, J. Kuusisto, M. Vanttinen et al., "Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion," *Diabetologia*, vol. 50, no. 6, pp. 1192–1200, 2007.
- [63] D. Dabelea, L. M. Dolan, R. D'Agostino et al., "Association testing of TCF7L2 polymorphisms with type 2 diabetes in multi-ethnic youth," *Diabetologia*, vol. 54, no. 3, pp. 535–539, 2011.
- [64] O. T. Raitakari, T. Rönnemaa, R. Huupponen et al., "Variation of the transcription factor 7-like 2 (TCF7L2) gene predicts impaired fasting glucose in healthy young adults. The Cardiovascular Risk in Young Finns Study," *Diabetes Care*, vol. 30, pp. 2299–2301, 2007.
- [65] T. Jin and L. Liu, "The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus," *Molecular Endocrinology*, vol. 22, no. 11, pp. 2383–2392, 2008.
- [66] T. Reya and H. Clevers, "Wnt signalling in stem cells and cancer," *Nature*, vol. 434, no. 7035, pp. 843–850, 2005.
- [67] I. C. Rulifson, S. K. Karnik, P. W. Heiser et al., "Wnt signaling regulates pancreatic β cell proliferation," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 15, pp. 6247–6252, 2007.

- [68] S. Papadopoulou and H. Edlund, "Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function," *Diabetes*, vol. 54, no. 10, pp. 2844–2851, 2005.
- [69] J. M. Wells, F. Esni, G. P. Boivin et al., "Wnt/ β -catenin signaling is required for development of the exocrine pancreas," *BMC Developmental Biology*, vol. 7, article 4, 2007.
- [70] P. W. Heiser, J. Lau, M. M. Taketo, P. L. Herrera, and M. Hebrok, "Stabilization of β -catenin impacts pancreas growth," *Development*, vol. 133, no. 10, pp. 2023–2032, 2006.
- [71] R. J. F. Loos, P. W. Franks, R. W. Francis et al., "TCF7L2 polymorphisms modulate proinsulin levels and β -cell function in a British europid population," *Diabetes*, vol. 56, no. 7, pp. 1943–1947, 2007.
- [72] V. Lyssenko, R. Lupi, P. Marchetti et al., "Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes," *Journal of Clinical Investigation*, vol. 117, no. 8, pp. 2155–2163, 2007.
- [73] D. T. Villareal, H. Robertson, G. I. Bell et al., "TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action," *Diabetes*, vol. 59, no. 2, pp. 479–485, 2010.
- [74] L. Shu, A. V. Matveyenko, J. Kerr-Conte, J. H. Cho, C. H. S. McIntosh, and K. Maedler, "Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function," *Human Molecular Genetics*, vol. 18, no. 13, pp. 2388–2399, 2009.
- [75] L. Shu, N. S. Sauter, F. T. Schulthess, A. V. Matveyenko, J. Oberholzer, and K. Maedler, "Transcription factor 7-like 2 regulates β -cell survival and function in human pancreatic islets," *Diabetes*, vol. 57, no. 3, pp. 645–653, 2008.
- [76] G. Da Silva Xavier, M. K. Loder, A. McDonald et al., "TCF7L2 regulates late events in insulin secretion from pancreatic islet β -cells," *Diabetes*, vol. 58, no. 4, pp. 894–905, 2009.
- [77] G. da Silva Xavier, A. Mondragon, G. Sun et al., "Abnormal glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-null mice," *Diabetologia*, vol. 55, pp. 2667–2676, 2012.
- [78] L. Prokunina-Olsson, C. Welch, O. Hansson et al., "Tissue-specific alternative splicing of TCF7L2," *Human Molecular Genetics*, vol. 18, no. 20, pp. 3795–3804, 2009.
- [79] Z. Liu and J. F. Habener, "Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation," *Journal of Biological Chemistry*, vol. 283, no. 13, pp. 8723–8735, 2008.
- [80] M. L. Slattery, A. R. Folsom, R. Wolff, J. Herrick, B. J. Caan, and J. D. Potter, "Transcription factor 7-like 2 polymorphism and colon cancer," *Cancer Epidemiology Biomarkers and Prevention*, vol. 17, no. 4, pp. 978–982, 2008.
- [81] A. Saadeddin, R. Babaei-Jadidi, B. Spencer-Dene, and A. S. Nateri, "The links between transcription, β -catenin/JNK signaling, and carcinogenesis," *Molecular Cancer Research*, vol. 7, no. 8, pp. 1189–1196, 2009.
- [82] J. Roose and H. Clevers, "TCF transcription factors: molecular switches in carcinogenesis," *Biochimica et Biophysica Acta*, vol. 1424, no. 2–3, pp. M23–M37, 1999.
- [83] V. Korinek, N. Barker, P. Moerer et al., "Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4," *Nature Genetics*, vol. 19, no. 4, pp. 379–383, 1998.
- [84] S. F. Boj, J. H. van Es, M. Huch et al., "Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand," *Cell*, vol. 151, no. 7, pp. 1595–1607, 2012.
- [85] D. Savic, H. Ye, I. Aneas, S. Y. Park, G. I. Bell, and M. A. Nobrega, "Alterations in TCF7L2 expression define its role as a key regulator of glucose metabolism," *Genome Research*, vol. 21, pp. 1417–1425, 2011.
- [86] H. Yang, Q. Li, J. H. Lee, and Y. Shu, "Reduction in Tcf7l2 expression decreases diabetic susceptibility in mice," *International Journal of Biological Sciences*, vol. 8, pp. 791–801, 2012.
- [87] N. Barker, G. Huls, V. Korinek, and H. Clevers, "Restricted high level expression of Tcf-4 protein in intestinal and mammary gland epithelium," *American Journal of Pathology*, vol. 154, no. 1, pp. 29–35, 1999.
- [88] M. Horikoshi, K. Hara, C. Ito, R. Nagai, P. Froguel, and T. Kadowaki, "A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population," *Diabetologia*, vol. 50, no. 4, pp. 747–751, 2007.
- [89] S. A. Schäfer, O. Tschritter, F. Machicao et al., "Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms," *Diabetologia*, vol. 50, no. 12, pp. 2443–2450, 2007.
- [90] G. Gu, J. Dubauskaite, and D. A. Melton, "Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors," *Development*, vol. 129, no. 10, pp. 2447–2457, 2002.
- [91] K. Hisadome, M. A. Smith, A. I. Choudhury, M. Claret, D. J. Withers, and M. L. J. Ashford, "5-HT inhibition of rat insulin 2 promoter Cre recombinase transgene and proopiomelanocortin neuron excitability in the mouse arcuate nucleus," *Neuroscience*, vol. 159, no. 1, pp. 83–93, 2009.
- [92] G. Sun, A. I. Tarasov, J. A. McGinty et al., "LKB1 deletion with the RIP2.Cre transgene modifies pancreatic β -cell morphology and enhances insulin secretion in vivo," *American Journal of Physiology: Endocrinology and Metabolism*, vol. 298, no. 6, pp. E1261–E1273, 2010.
- [93] G. Sun, R. Reynolds, I. Leclerc, and G. A. Rutter, "RIP2-mediated LKB1 deletion causes axon degeneration in the spinal cord and hind-limb paralysis," *DMM Disease Models and Mechanisms*, vol. 4, no. 2, pp. 193–202, 2011.
- [94] L. Shu, K. Zien, G. Gutjahr et al., "TCF7L2 promotes beta cell regeneration in human and mouse pancreas," *Diabetologia*, vol. 55, pp. 3296–3307, 2012.
- [95] B. Wicksteed, M. Brissova, W. Yan et al., "Conditional gene targeting in mouse pancreatic β -cells: analysis of ectopic cre transgene expression in the brain," *Diabetes*, vol. 59, no. 12, pp. 3090–3098, 2010.
- [96] Y. Dor, J. Brown, O. I. Martinez, and D. A. Melton, "Adult pancreatic β -cells are formed by self-duplication rather than stem-cell differentiation," *Nature*, vol. 429, no. 6987, pp. 41–46, 2004.
- [97] T. J. Nicolson, E. A. Bellomo, N. Wijesekara et al., "Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants," *Diabetes*, vol. 58, no. 9, pp. 2070–2083, 2009.
- [98] A. B. Hardy, N. Wijesekara, I. Genkin et al., "Effects of high-fat diet feeding on Znt8-null mice: differences between beta-cell and global knockout of Znt8," *American Journal of Physiology: Endocrinology and Metabolism*, vol. 302, pp. E1084–E1096, 2012.
- [99] K. Lemaire, M. A. Ravier, A. Schraenen et al., "Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 35, pp. 14872–14877, 2009.

- [100] L. D. Pound, S. A. Sarkar, R. K. P. Benninger et al., "Deletion of the mouse *Slc30a8* gene encoding zinc transporter-8 results in impaired insulin secretion," *Biochemical Journal*, vol. 421, no. 3, pp. 371–376, 2009.
- [101] L. D. Pound, S. A. Sarkar, A. Ustione et al., "The physiological effects of deleting the mouse *SLC30A8* gene encoding zinc transporter-8 are influenced by gender and genetic background," *PLoS ONE*, vol. 7, Article ID e40972, 2012.
- [102] N. Wijesekara, F. F. Dai, A. B. Hardy et al., "Beta cell-specific *Znt8* deletion in mice causes marked defects in insulin processing, crystallisation and secretion," *Diabetologia*, vol. 53, no. 8, pp. 1656–1668, 2010.
- [103] K. J. Gaulton, T. Nammo, L. Pasquali et al., "A map of open chromatin in human pancreatic islets," *Nature Genetics*, vol. 42, no. 3, pp. 255–259, 2010.
- [104] A. Duval, S. Rolland, E. Tubacher, H. Bui, G. Thomas, and R. Hamelin, "The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines," *Cancer Research*, vol. 60, no. 14, pp. 3872–3879, 2000.
- [105] O. Le Bacquer, L. Shu, M. Marchand et al., "TCF7L2 splice variants have distinct effects on β -cell turnover and function," *Human Molecular Genetics*, vol. 20, no. 10, pp. 1906–1915, 2011.
- [106] A. K. Mondal, S. K. Das, G. Baldini et al., "Genotype and tissue-specific effects on alternative splicing of the transcription factor 7-like 2 gene in humans," *Journal of Clinical Endocrinology and Metabolism*, vol. 95, no. 3, pp. 1450–1457, 2010.
- [107] A. Weise, K. Bruser, S. Elfert et al., "Alternative splicing of *Tcf7l2* transcripts generates protein variants with differential promoter-binding and transcriptional activation properties at *Wnt*/ β -catenin targets," *Nucleic Acids Research*, vol. 38, no. 6, pp. 1964–1981, 2009.
- [108] L. A. Lichten and R. J. Cousins, "Mammalian zinc transporters: nutritional and physiologic regulation," *Annual Review of Nutrition*, vol. 29, pp. 153–176, 2009.
- [109] F. Chimienti, S. Devergnas, A. Favier, and M. Seve, "Identification and cloning of a β -cell-specific zinc transporter, *ZnT-8*, localized into insulin secretory granules," *Diabetes*, vol. 53, no. 9, pp. 2330–2337, 2004.
- [110] F. Chimienti, A. Favier, and M. Seve, "ZnT-8, a pancreatic β -cell-specific zinc transporter," *BioMetals*, vol. 18, no. 4, pp. 313–317, 2005.
- [111] S. O. Emdin, G. G. Dodson, J. M. Cutfield, and S. M. Cutfield, "Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell," *Diabetologia*, vol. 19, no. 3, pp. 174–182, 1980.
- [112] G. A. Rutter, "Think zinc: new roles for zinc in the control of insulin secretion," *Islets*, vol. 2, no. 1, pp. 49–50, 2010.
- [113] E. D. Berglund, C. Y. Li, G. Poffenberger et al., "Glucose metabolism in vivo in four commonly used inbred mouse strains," *Diabetes*, vol. 57, no. 7, pp. 1790–1799, 2008.
- [114] A. T. Hattersley, "Unlocking the secrets of the pancreatic β cell: man and mouse provide the key," *Journal of Clinical Investigation*, vol. 114, no. 3, pp. 314–316, 2004.
- [115] D. Reyon, S. Q. Tsai, C. Khayter, J. A. Foden, J. D. Sander, and J. K. Joung, "FLASH assembly of TALENs for high-throughput genome editing," *Nature Biotechnology*, vol. 30, pp. 460–465, 2012.
- [116] C. Mussolino and T. Cathomen, "TALE nucleases: tailored genome engineering made easy," *Current Opinion in Biotechnology*, vol. 23, pp. 644–650, 2012.
- [117] D. Hockemeyer, H. Wang, S. Kiani et al., "Genetic engineering of human pluripotent cells using TALE nucleases," *Nature Biotechnology*, vol. 29, no. 8, pp. 731–734, 2011.
- [118] J. B. Meigs, P. Shrader, L. M. Sullivan et al., "Genotype score in addition to common risk factors for prediction of type 2 diabetes," *New England Journal of Medicine*, vol. 359, no. 21, pp. 2208–2219, 2008.
- [119] V. Lyssenko, A. Jonsson, P. Almgren et al., "Clinical risk factors, DNA variants, and the development of type 2 diabetes," *New England Journal of Medicine*, vol. 359, no. 21, pp. 2220–2232, 2008.
- [120] P. J. Talmud, A. D. Hingorani, J. A. Cooper et al., "Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: whitehall II prospective cohort study," *British Medical Journal*, vol. 340, article b4838, 2010.
- [121] H. Langothe, C. N. A. Palmer, A. D. Morris et al., "Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk," *Diabetes*, vol. 57, no. 11, pp. 3129–3135, 2008.
- [122] R. K. Simmons, A. H. Harding, N. J. Wareham, and S. J. Griffin, "Do simple questions about diet and physical activity help to identify those at risk of Type 2 diabetes?" *Diabetic Medicine*, vol. 24, no. 8, pp. 830–835, 2007.
- [123] J. Lindström and J. Tuomilehto, "The diabetes risk score: a practical tool to predict type 2 diabetes risk," *Diabetes Care*, vol. 26, no. 3, pp. 725–731, 2003.
- [124] M. C. Cornelis, L. Qi, P. Kraft, and F. B. Hu, "TCF7L2, dietary carbohydrate, and risk of type 2 diabetes in US women," *American Journal of Clinical Nutrition*, vol. 89, no. 4, pp. 1256–1262, 2009.
- [125] E. Fisher, H. Boeing, A. Fritsche, F. Doering, H. G. Joost, and M. B. Schulze, "Whole-grain consumption and transcription factor-7-like 2 (*TCF7L2*) rs7903146: gene-diet interaction in modulating type 2 diabetes risk," *British Journal of Nutrition*, vol. 101, no. 4, pp. 478–481, 2009.
- [126] A. Haupt, C. Thamer, M. Heni et al., "Gene variants of *TCF7L2* influence weight loss and body composition during lifestyle intervention in a population at risk for type 2 diabetes," *Diabetes*, vol. 59, no. 3, pp. 747–750, 2010.
- [127] T. Reinehr, S. Friedel, T. D. Mueller, A. M. Toschke, J. Hebebrand, and A. Hinney, "Evidence for an influence of *TCF7L2* polymorphism rs7903146 on insulin resistance and sensitivity indices in overweight children and adolescents during a lifestyle intervention," *International Journal of Obesity*, vol. 32, no. 10, pp. 1521–1524, 2008.
- [128] D. Thomas, "Gene—environment-wide association studies: emerging approaches," *Nature Reviews Genetics*, vol. 11, no. 4, pp. 259–272, 2010.
- [129] U. Smith and E. A. M. Gale, "Cancer and diabetes: are we ready for prime time?" *Diabetologia*, vol. 53, no. 8, pp. 1541–1544, 2010.
- [130] W. Y. Kim and N. E. Sharpless, "The Regulation of *INK4/ARF* in Cancer and Aging," *Cell*, vol. 127, no. 2, pp. 265–275, 2006.
- [131] J. Krishnamurthy, M. R. Ramsey, K. L. Ligon et al., "p16^{INK4a} induces an age-dependent decline in islet regenerative potential," *Nature*, vol. 443, no. 7110, pp. 453–457, 2006.
- [132] S. G. Rane, P. Dubus, R. V. Mettus et al., "Loss of *Cdk4* expression causes insulin-deficient diabetes and *Cdk4* activation results in β -islet cell hyperplasia," *Nature Genetics*, vol. 22, no. 1, pp. 44–54, 1999.
- [133] L. M. Holdt and D. Teupser, "Recent studies of the human chromosome 9p21 locus, which is associated with atherosclerosis in

- human populations,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 32, pp. 196–206, 2012.
- [134] E. Pasmant, I. Laurendeau, D. Héron, M. Vidaud, D. Vidaud, and I. Bièche, “Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF,” *Cancer Research*, vol. 67, no. 8, pp. 3963–3969, 2007.
- [135] A. Visel, Y. Zhu, D. May et al., “Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice,” *Nature*, vol. 464, no. 7287, pp. 409–412, 2010.
- [136] J. Gudmundsson, P. Sulem, V. Steinthorsdottir et al., “Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes,” *Nature Genetics*, vol. 39, no. 8, pp. 977–983, 2007.
- [137] G. Thomas, K. B. Jacobs, M. Yeager et al., “Multiple loci identified in a genome-wide association study of prostate cancer,” *Nature Genetics*, vol. 40, pp. 310–315, 2008.
- [138] P. Ravassard, Y. Hazhouz, S. Pechberty et al., “A genetically engineered human pancreatic beta cell line exhibiting glucose-inducible insulin secretion,” *Journal of Clinical Investigation*, vol. 121, pp. 3589–3597, 2011.
- [139] B. Seidler, A. Schmidt, U. Mayr et al., “A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 29, pp. 10137–10142, 2008.